Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →This landscape draws on 33 published patent records filed between 2015 and 2026 that combine peripheral nerve interface claims with sensory feedback mechanisms for prosthetic limbs — vibrotactile stimulation, targeted muscle reinnervation, closed-loop control, and related electrode and embodiment claims. The scope is narrow by design: it isolates the intersection of nerve interfacing and prosthesis sensory return, not prosthetics broadly.
Coverage runs through the 2026-07-31 cut-off. Because publication typically lags filing by around 18 months, the most recent year's count understates real filing activity and should be read as a floor, not a ceiling.
Pick a task. Every answer cites the patents behind it.
Two views of the same 33 records: how filing activity has moved year over year, and how those records distribute across the IPC subclasses that define this technology's claim space.
Activity sat at zero through 2017 and stayed low until a sharp rise to 28 records in 2024, the peak year so far. With too few complete post-lag years to compute a reliable growth rate, treat this as a technology that arrived late and concentrated rather than one with a steady multi-year build-up.
A61F (implants & prostheses) appears in 87.9% of the 33 records, confirming that most claims are anchored to physical prosthetic or implant hardware. A61N (electrotherapy) at 57.6% and A61B (diagnosis & surgery) at 48.5% show that stimulation and sensing claims are nearly as common, often layered onto the same filings. A61L (sterilising & disinfecting) at 9.1% marks a comparatively thin, secondary claim area.
Shares are the percentage of the 33 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about sensory feedback in prosthetic limbs and every answer comes back with the patent numbers behind it.
Try EurekaThe disclosure describes a regenerative peripheral nerve interface (RPNI) built from an insulating substrate with a thin-film metallic electrode array, part of which is coated with a first conductive polymer and a layer of decellularized small intestinal submucosa (SIS). A second conductive polymer is electrochemically polymerized through the SIS to complete the interface, and a layer of muscle tissue contacts the assembly directly.Filed by The Regents of the University of Michigan, published 2017-11-07.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20130304174A1 | Peripheral nerve interface devices for treatment and prevention of neuromas | 81 |
| 2 | US20140005763A1 | Regenerative peripheral nerve interface | 32 |
| 3 | WO2012097297A2 | Regenerative peripheral nerve interface | 27 |
| 4 | US9352146B2 | Peripheral nerve interface devices for treatment and prevention of neuromas | 24 |
| 5 | US9808616B2 | Regenerative peripheral nerve interface | 7 |
Ranked by citation count within this search corpus; older filings accumulate citations simply by being available longer, so treat this as a signal of influence rather than current relevance.
Publication numbers are shown where the record carries one (5 of 5 rows); clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the ranking, trend and citation data together points to a field defined more by a small research cluster than by broad industry competition.
The ranked leader accounts for 33 of the tracked families while fifth place holds just 1. With only six assignees in the entire ranking, this reads as a research-driven niche anchored by one institution rather than a competitive multi-company race.
Filings stayed near zero for years before jumping to 28 in the peak year. Because publication lags filing by roughly 18 months, 2025-2026 counts will keep rising as more records surface — the current trend line is a floor.
Implant and prosthesis hardware (A61F) sits in the large majority of the 33 records, with electrotherapy (A61N) and diagnosis/surgery (A61B) claims frequently layered on top. Sterilising and disinfecting claims (A61L) appear in under a tenth of records, marking comparatively open ground.
The strongest co-assignee pairs each recur three times and involve the same small group of individual researchers alongside the lead university. This is the signature of a lab-based inventing team rather than a licensing or manufacturing network.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to sensory feedback in prosthetic limbs, with the prior art for and against each one.
Six assignees make up the entire ranking for this search, led by one university with the rest holding a handful of records each — a pattern typical of an emerging, research-origin technology rather than a mature industrial one.
The top-ranked assignee holds the full leader count of 33 tracked families, built through repeated collaboration with the same named inventors across regenerative peripheral nerve interface work.
Beyond the leader, a second university and a small set of named individual inventors round out the ranking, with the fifth-place holder at just 1 family — there is no visible mid-tier of competitors.
Co-assignee analysis shows three individual researchers pairing repeatedly at a strength of 3, indicating a core inventing team whose output accounts for a large share of the dataset's most-cited records.
| Assignee | Recent year | YoY |
|---|---|---|
| The Regents of the University of Michigan | 0 | — |
| URBANCHEK MELANIE G | 0 | — |
| MARTIN DAVID C | 0 | — |
| CEDERNA PAUL S | 0 | — |
| University of Delaware | 0 | — |
The dataset points to a concentrated, recent field with specific claim gaps. These next steps help translate that into freedom-to-operate and whitespace decisions.
Before filing near regenerative peripheral nerve interface hardware, check dependent claims in the leader's family tree for coating, substrate and electrode-array limitations that recur across its most-cited filings.
Explore the leader's portfolio in Eureka →A61L and prosthesis embodiment claims are thin relative to the core hardware and electrotherapy classes, suggesting room for claims combining electrode longevity with sterilisation methods.
Run a whitespace search in Eureka →Because of publication lag, records from 2025-2026 are still arriving. Re-run this search periodically to catch new entrants before a freedom-to-operate opinion goes stale.
Set up monitoring in Eureka →Within this dataset of 33 published records, the ranked leader holds 33 tracked families, a University of Michigan-affiliated filer working with a small group of named inventors on regenerative peripheral nerve interface technology. The next-closest institution in the six-name ranking is a fair distance behind, and the fifth-place assignee holds only 1 family. This is a concentrated field led by academic research groups rather than a broad set of competing manufacturers, so freedom-to-operate work should start with the leader's family tree before looking elsewhere.
The representative record in this dataset, US9808616B2, claims an RPNI built from an insulating substrate carrying a thin-film metallic electrode array, part of it coated with a conductive polymer and a layer of decellularized small intestinal submucosa (SIS), with a second conductive polymer electrochemically polymerized through the SIS and muscle tissue placed in contact with the assembly. In practice this locks down a specific electrode-coating and tissue-interface construction rather than the general concept of nerve interfacing. Designs that avoid the SIS coating and dual-polymer polymerization step have more room to operate, though they still need to clear the wider family of related filings from the same assignee.
Filing activity was near zero through 2017 and stayed low for several years before jumping to a peak of 28 records in 2024. There are not yet enough complete years after accounting for publication lag to state a reliable growth rate, so any trend line drawn from this data should be treated as provisional. What can be said is that the field's patent activity is recent and concentrated around a short window rather than built up steadily since 2015.
Sterilising and disinfecting claims (A61L) appear in only 9.1% of the 33 records in scope, a much thinner share than the 87.9% covered by implant and prosthesis hardware claims (A61F) or the 57.6% covered by electrotherapy claims (A61N). Sub-areas like electrode longevity coatings, closed-loop sensory calibration, and prosthesis embodiment ergonomics also show comparatively few dedicated filings relative to the core hardware classes. These pockets are worth a closer prior-art search before assuming the space is closed, since low filing density in a narrow scope like this can reflect real gaps rather than saturation.
PCT filings through WIPO lead with 9 records, followed by Israel at 8. Australia, Canada, Europe (EPO) and the United States each show 4 records. The spread across multiple receiving offices for a relatively small 33-record dataset suggests applicants are pursuing international protection early, likely through PCT applications, rather than filing narrowly in a single home jurisdiction.
Go past this page: query the whole sensory feedback in prosthetic limbs corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page